Characterization of a New AAV Vector Targeting Expression of Transthyretin to the Correct Tissues after Systemic Delivery in Mice

被引：0
|
作者：
Batista, Ana Rita [1 ]
Sena-Esteves, Miguel [1 ]
机构：
[1] Univ Massachussets, Sch Med, Dept Neurol, Horae Gene Therapy Ctr, Worcester, MA USA
来源：
MOLECULAR THERAPY | 2019年 / 27卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
185
引用
收藏
页码：97 / 97
页数：1
相关论文
共 43 条
  • [1] Reduction of Transthyretin Expression by AAV Gene Delivery of a Novel Endonuclease in Mice
    Greig, Jenny A.
    Ashley, Scott N.
    Gorsuch, Cassandra
    Chorazeczewski, Joanna
    Furmanak, Thomas
    Zhu, Yanqing
    Bell, Peter
    Sharer, Wendy
    Li, Hui
    Smith, Jeff
    Clark, Peter
    Breton, Camilo
    Wilson, James M.
    MOLECULAR THERAPY, 2019, 27 (04) : 463 - 463
  • [2] Improved Targeting and Transduction Efficiency in the Central Nervous System After Systemic Delivery of an AAV-Derived Vector
    Rincon, Melvin Y.
    Duque, Sandra I.
    Wenger, Jessica Bouhuijzen
    de Vin, Filip
    Holt, Matthew
    MOLECULAR THERAPY, 2017, 25 (05) : 199 - 200
  • [3] Transduction and Expression in Brain after Systemic Delivery of Single Stranded AAV9 in Adult Mice
    Keeler, Allison M.
    Sena-Esteves, Miguel
    Conlon, Thomas
    Erger, Kirsten
    Fu Dongtao
    Flotte, Terence R.
    MOLECULAR THERAPY, 2012, 20 : S228 - S228
  • [4] Analysis of vector genome integration sites in various tissues following systemic administration of AAV serotype 8 vector in mice
    Inagaki, K
    Wu, XL
    Fuess, S
    Storm, TA
    Kay, MA
    Nakai, H
    JOURNAL OF GENE MEDICINE, 2006, 8 (03): : 391 - 391
  • [5] Sustained expression and safety of human GNE in normal mice after gene transfer based on AAV8 systemic delivery
    Mitrani-Rosenbaum, Stella
    Yakovlev, Lena
    Cohen, Michal Becker
    Telem, Michal
    Elbaz, Moran
    Yanay, Nurit
    Yotvat, Hagit
    Ben Shlomo, Uri
    Harazi, Avi
    Fellig, Yakov
    Argov, Zohar
    Sela, Ilan
    NEUROMUSCULAR DISORDERS, 2012, 22 (11) : 1015 - 1024
  • [6] A Comparison of CNS Transduction After Systemic versus Cranial Delivery of an AAV2/9 CamKII Promoter-eGFP Vector in Mice
    Gibson, Alana L.
    Chandler, Randy J.
    Williams, Ian M.
    Incao, Arturo A.
    Porter, Forbes D.
    Pavan, William J.
    Venditti, Charles P.
    MOLECULAR THERAPY, 2016, 24 : S243 - S243
  • [7] Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector
    Choudhury, Sourav R.
    Harris, Anne F.
    Cabral, Damien J.
    Keeler, Allison M.
    Sapp, Ellen
    Ferreira, Jennifer S.
    Gray-Edwards, Heather L.
    Johnson, Jacob A.
    Johnson, Aime K.
    Su, Qin
    Stoica, Lorelei
    DiFiglia, Marian
    Aronin, Neil
    Martin, Douglas R.
    Gao, Guangping
    Sena-Esteves, Miguel
    MOLECULAR THERAPY, 2016, 24 (04) : 726 - 735
  • [8] An AAV Capsid Mediates Highly Selective Transduction of Brain Endothelium and Pericytes after Systemic Delivery in Mice
    McCarthy, Siobhan
    Hanlon, Killian S.
    Hudry, Eloise
    Nammour, Josette
    Musolino, Patricia L.
    Maguire, Casey A.
    MOLECULAR THERAPY, 2021, 29 (04) : 158 - 158
  • [9] AAV-2-mediated expression of α-N-acetyl-glucosaminidase in peripheral tissues and the CNS in mucopolysaccharidosis IIIB mice by combined intravenous and intracisternal vector delivery
    Kang, L
    Jennings, JS
    Muenzer, J
    Fu, HY
    MOLECULAR THERAPY, 2004, 9 : S328 - S329
  • [10] A muscle hybrid promoter provides specific and effective gene expression after intramuscular and systemic delivery with AAV
    Piekarowicz, K.
    Beuvin, M.
    Machowska, M.
    Bertrand, A.
    Bonne, G.
    Rzepecki, R.
    HUMAN GENE THERAPY, 2017, 28 (12) : A44 - A45
12345